Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Status:
Terminated
Trial end date:
2017-02-17
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to evaluate the effect of eleclazine (GS-6615) on
exercise capacity as measured by Peak oxygen uptake (VO2) achieved during cardiopulmonary
exercise testing (CPET), in participants with symptomatic hypertrophic cardiomyopathy (HCM).